In Zimbabwe, Friendship Bench, a community-based approach is providing solutions to people struggling with their mental health during this pandemic.

If vaccine efficacy can’t be assessed through placebo-controlled trials in future, how can we know if they are effective?

The initial concern that nervousness over the new vaccines would slow uptake doesn’t seem to have become a reality in the early days of COVID-19 immunisation, although it will be critical to maintain vaccine confidence suggests an Ipsos poll.

Scientists have observed that 501Y.V2 has quickly become "dominant" among multiple variants that have been circulating in the South African population.

It’s time-consuming but worthwhile: Residents respond to messages about Covid testing and vaccines when outreach teams speak their language and make a personal connection.

Zambian data challenges the assumption African populations may have been spared from COVID-19.

Will these rapid tests really allow us to lower our guard during the pandemic?

Without a vaccine, the worldwide economic impact of COVID-19 would have been $3.4 trillion a year. But even with a COVID-19 vaccine, unequal allocation could cost the global economy up to $1.2 trillion a year in GDP.

COVID-19 is deepening global food insecurity, as the pandemic’s economic impact adds to existing challenges.

Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.

A medical professor explains the reasoning behind the delay in the UK and what impact this might have on the vaccine's effectiveness.

COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.